Product image of Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Milpharm (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide) supplied by GNH India

Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Milpharm

Active Ingredient:
Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide
Origin:
EU

Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Milpharm (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Milpharm, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑drug therapy is insufficient.

GNH India supplies Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Milpharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide is indicated for hypertension and works within the cardiovascular system to lower blood pressure.

  • Hypertension: provides additive blood‑pressure reduction when monotherapy does not achieve target levels.
  • Hypertensive patients with edema: counteracts amlodipine‑induced peripheral edema while controlling pressure.
  • Hypertension with fluid retention: adds diuretic effect of hydrochlorothiazide to improve overall control.

How It Works

  • The combination couples three mechanisms: olmesartan blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal tubule, decreasing plasma volume. Together they produce a synergistic antihypertensive effect.

Side Effects

Adverse reactions may appear as either frequent, mild events or rare, serious conditions.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Dizziness or light‑headedness: especially after the first doses.
  • Peripheral edema: swelling of ankles or feet.
  • Flushing: transient warmth sensation.
  • Fatigue: general tiredness.
  • Increased urination: due to the diuretic component.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure causing fainting.
  • Hyperkalemia or hyponatremia: electrolyte disturbances.
  • Acute kidney injury: sudden decline in renal function.
  • Angio‑edema: swelling of lips, tongue or airway.
  • Liver enzyme elevation: abnormal hepatic function tests.
  • Blood dyscrasias: rare blood‑cell abnormalities.

Precautions & Warnings

Before prescribing this combination, clinicians should evaluate patient history and monitor key parameters.

  • Renal function: assess creatinine clearance before initiation and periodically thereafter.
  • Electrolyte balance: check serum potassium and sodium levels, especially with diuretic use.
  • Hepatic impairment: use caution in patients with liver disease.
  • Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
  • Concomitant antihypertensives: monitor for additive hypotensive effect.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid)

  • Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine exposure.
  • Lithium: concurrent use can raise lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response.
  • ACE inhibitors or other ARBs: additive effect on potassium and renal function.
  • Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.

Frequently Asked Questions

It is a fixed‑dose combination used to lower high blood pressure in adults, especially when a single antihypertensive agent does not achieve target readings. The three components work together to relax blood vessels and reduce fluid volume, helping to control hypertension.

Olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction. Amlodipine adds arterial dilation by inhibiting calcium entry into smooth‑muscle cells, and hydrochlorothiazide promotes sodium and water excretion. The combined actions produce a synergistic reduction in blood pressure.

The dose is individualized by the prescribing clinician based on the patient’s blood‑pressure level, renal function and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

The combination is contraindicated in pregnancy, particularly in the second and third trimesters, because of potential fetal harm. Limited data are available for breastfeeding; therefore, it should be used only if the potential benefit justifies the possible risk to the infant.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑agent therapy, the triple combination offers greater blood‑pressure reduction and can simplify regimens by reducing pill burden. It is especially useful when patients need an ARB, a calcium‑channel blocker and a thiazide‑type diuretic together, whereas alternatives may require multiple separate tablets.

Store below 25 °C in the original packaging, protecting it from moisture and direct sunlight. Do not expose the tablets to excessive heat or humidity to maintain potency.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional.

Serious risks include severe hypotension, electrolyte disturbances such as hyperkalemia or hyponatremia, acute kidney injury, angio‑edema and rare blood‑cell abnormalities. Patients should be monitored for these events, especially during treatment initiation.

Patients with known hypersensitivity to any component, those in the second or third trimester of pregnancy, individuals with severe renal or hepatic impairment, and patients taking contraindicated drugs such as potassium‑sparing diuretics should avoid this combination.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT